Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.022 | 0.7 |
mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.028 | 0.7 |
mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.7 |